Additive value of [
Neuronal injury
PET
Perfusion
Tau
[18F]PI-2620
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
17
01
2022
accepted:
01
09
2022
pubmed:
15
9
2022
medline:
10
1
2023
entrez:
14
9
2022
Statut:
ppublish
Résumé
Early after [ Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [ Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R = - 0.431; p = 0.0005). [
Identifiants
pubmed: 36102964
doi: 10.1007/s00259-022-05964-w
pii: 10.1007/s00259-022-05964-w
pmc: PMC9816230
doi:
Substances chimiques
PI-2620
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-434Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2145 SyNergy - ID 390857198
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHR 774/5-1
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EK1605A HitTau
Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2022. The Author(s).
Références
Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19. https://doi.org/10.1001/jamaneurol.2020.2526 .
doi: 10.1001/jamaneurol.2020.2526
Palleis C, Brendel M, Finze A, Weidinger E, Botzel K, Danek A, et al. Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord. 2021;36:2104–15. https://doi.org/10.1002/mds.28624 .
doi: 10.1002/mds.28624
Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. Neuron. 2021;109(42–58): e8. https://doi.org/10.1016/j.neuron.2020.09.042 .
doi: 10.1016/j.neuron.2020.09.042
Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126:238–92. https://doi.org/10.1016/j.brainresbull.2016.08.018 .
doi: 10.1016/j.brainresbull.2016.08.018
Rosler TW, TayaranianMarvian A, Brendel M, Nykanen NP, Hollerhage M, Schwarz SC, et al. Four-repeat tauopathies. Prog Neurobiol. 2019;180:101644. https://doi.org/10.1016/j.pneurobio.2019.101644 .
doi: 10.1016/j.pneurobio.2019.101644
Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019;92:e1121–35. https://doi.org/10.1212/WNL.0000000000007038 .
doi: 10.1212/WNL.0000000000007038
Khosravi M, Peter J, Wintering NA, Serruya M, Shamchi SP, Werner TJ, et al. 18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer’s disease and mild cognitive impairment evaluation: a global quantitative analysis. J Alzheimers Dis. 2019;70:1197–207. https://doi.org/10.3233/JAD-190220 .
doi: 10.3233/JAD-190220
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47. https://doi.org/10.1212/wnl.0000000000002923 .
doi: 10.1212/wnl.0000000000002923
Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64. https://doi.org/10.1002/mds.26987 .
doi: 10.1002/mds.26987
Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, et al. Dual-phase β-amyloid PET captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284. https://doi.org/10.3389/fnagi.2021.661284 .
doi: 10.3389/fnagi.2021.661284
Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, et al. Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47:2911–22. https://doi.org/10.1007/s00259-020-04788-w .
doi: 10.1007/s00259-020-04788-w
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301–9. https://doi.org/10.1016/j.dadm.2019.01.011 .
doi: 10.1016/j.dadm.2019.01.011
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503. https://doi.org/10.1212/WNL.0b013e31827f0fd1 .
doi: 10.1212/WNL.0b013e31827f0fd1
Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer’s disease neuroimaging initiative 2 PET core: 2015. Alzheimers Dement. 2015;11:757–71. https://doi.org/10.1016/j.jalz.2015.05.001 .
doi: 10.1016/j.jalz.2015.05.001
Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, et al. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48:3872–85. https://doi.org/10.1007/s00259-021-05391-3 .
doi: 10.1007/s00259-021-05391-3
Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, et al. Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin. 2017;14:77–86. https://doi.org/10.1016/j.nicl.2016.10.005 .
doi: 10.1016/j.nicl.2016.10.005
Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26:3508–26. https://doi.org/10.1093/cercor/bhw157 .
doi: 10.1093/cercor/bhw157
Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904–11.
Thomas BA, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton BF, et al. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys Med Biol. 2016;61:7975–93. https://doi.org/10.1088/0031-9155/61/22/7975 .
doi: 10.1088/0031-9155/61/22/7975
Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage. 2009;45:1241–52. https://doi.org/10.1016/j.neuroimage.2008.12.063 .
doi: 10.1016/j.neuroimage.2008.12.063
Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430–43. https://doi.org/10.1002/ana.24885 .
doi: 10.1002/ana.24885
Parmera JB, Coutinho AM, Aranha MR, Studart-Neto A, de Godoi CC, de Almeida IJ, et al. FDG-PET patterns predict amyloid deposition and clinical profile in corticobasal syndrome. Mov Disord. 2020. https://doi.org/10.1002/mds.28373 .
doi: 10.1002/mds.28373
Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018;45:1534–45. https://doi.org/10.1007/s00259-018-4031-2 .
doi: 10.1007/s00259-018-4031-2
Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26:627–45. https://doi.org/10.3233/JAD-2011-110458 .
doi: 10.3233/JAD-2011-110458
Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. The Lancet Neurology. 2010;9:149–58. https://doi.org/10.1016/S1474-4422(10)70002-8 .
doi: 10.1016/S1474-4422(10)70002-8
Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014;137:3036–46. https://doi.org/10.1093/brain/awu256 .
doi: 10.1093/brain/awu256
Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23:727–33. https://doi.org/10.1002/mds.21933 .
doi: 10.1002/mds.21933
Höglinger GU. Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No Movement disorders clinical practice. 2018;5:141.
doi: 10.1002/mdc3.12582
Albrecht F, Bisenius S, Neumann J, Whitwell J, Schroeter ML. Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis. Neuroimage Clin. 2019;22: 101722. https://doi.org/10.1016/j.nicl.2019.101722 .
doi: 10.1016/j.nicl.2019.101722
Peng S, Tang C, Schindlbeck K, Rydzinski Y, Dhawan V, Spetsieris PG, et al. Dynamic (18)F-FPCIT PET: Quantification of Parkinson’s disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.257345 .
doi: 10.2967/jnumed.120.257345
Willroider M, Roeber S, Horn AKE, Arzberger T, Scheifele M, Respondek G, et al. Superiority of formalin-fixed paraffin-embedded brain tissue for in vitro assessment of progressive supranuclear palsy tau pathology with [(18) F]PI-2620. Front Neurol. 2021;12: 684523. https://doi.org/10.3389/fneur.2021.684523 .
doi: 10.3389/fneur.2021.684523
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570–6. https://doi.org/10.2967/jnumed.112.113654 .
doi: 10.2967/jnumed.112.113654
Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J, et al. [(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2017;9:440. https://doi.org/10.3389/fnagi.2017.00440 .
doi: 10.3389/fnagi.2017.00440
Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ, et al. MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov Disord. 2019;34:105–13. https://doi.org/10.1002/mds.27546 .
doi: 10.1002/mds.27546